Braun Medical Uses Needle-Trap from Schreiner MediPharm for New Prefilled Heparin Syringe

Schreiner MediPharm has collaborated with B. Braun Medical Inc. who recently launched its prefilled syringe of Heparin Sodium Injection, USP utilizing Schreiner MediPharm’s label-integrated Needle-Trap system to the US market.  According to B. Braun, this is the first prefilled heparin syringe with an integrated needle protection device approved by the US FDA.

In the US, syringes should be used with safety devices to protect healthcare staff against the risk of needlestick injuries. B. Braun Medical was looking for an efficient and safe needle protection solution for its prefilled Heparin Sodium Injection and found it in Needle-Trap from Schreiner MediPharm.

The Needle-Trap system is an internationally established solution that complies with the US NIOSH requirements for safe instruments and has been awarded 510(k) Pre-Market Notification by the FDA for marketing in the US.

“Clinical staff benefit from reliable protection against needlestick injuries because Needle-Trap’s activation is easy and irreversible. It is intuitive to use and requires no change in injection technique,” said Gene Dul, President of Schreiner MediPharm US.

Needle-Trap is the only label-based needle protection system on the market. The plastic needle trap is an integral component of the marking label and serves to secure the needle after the injection has been performed. Due to its special construction, Needle-Trap can easily and cost-efficiently be integrated into existing pharmaceutical production processes. It requires only minor modifications of the application systems, no changes to secondary packaging, and minimal space during shipping, storage and disposal.

“Our products are designed to increase patient and clinician safety, while reducing medication errors and improving dosage accuracy and workflows. Obviously, efficient and economical manufacturing are equally important. Collaborating with Schreiner MediPharm allowed us to meet those needs,” added Leigh Nickens, Director of Marketing, Fluid Therapy and Injectable Drugs at B. Braun.

Based in the Munich area of Germany, Schreiner MediPharm is a global leader in the development and manufacture of innovative specialty labels with value-added benefits that have set the standard in the healthcare and pharmaceutical industries. Schreiner MediPharm’s expertise is based on over 65 years of experience. The family-owned company provides specialty labels and label printing services to the biggest names in the healthcare market in over 20 countries around the world, including Japan.

Schreiner MediPharm’s US facility, a business unit of Schreiner Group LP, is located at 300 Corporate Drive, Suite 10, Blauvelt, NY 10913. For more information, visit www.schreiner-medipharm.com.

Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. Other key product areas include nutrition, pharmacy admixture and compounding, ostomy and wound care, and dialysis. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, PA, and is part of the B. Braun Group of Companies in the US, which includes B. Braun Interventional Systems, Aesculap and CAPS. Globally, the B. Braun Group of Companies employs more than 61,000 employees in 64 countries. Guided by its Sharing Expertise philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. For more information, visit www.BBraunUSA.com.